Company intelligence / Profile preview
Lytix Biopharma
Oslo, Norwaylytixbiopharma.com ↗
- Ownership
- Public · LYTIX
- Employees
- ~8
- Development stage
- Phase 2
01
Overview
LTX-315 achieved 97% calculated objective response rate in Phase II study for basal cell carcinoma; 40% disease control in late-stage melanoma with response lasting up to 22 months in ATLAS-IT-05 study; preparing for Phase III discussions with FDA in H1 2025
- Therapeutic areas
- Oncology
- Modalities
- Oncolytic peptideshost-defense peptide-derived molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Verrica Pharmaceuticals Inc.
04
Financials
- Market cap
- $64.7M
- Total revenue
- $0
- Enterprise value
- $55.1M
Beyond the preview
Go deeper on Lytix Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lytix Biopharma.